(MMSI) Merit Medical Systems - Ratings and Ratios
Catheters, Guidewires, Stents, Balloons, Needles
MMSI EPS (Earnings per Share)
MMSI Revenue
Description: MMSI Merit Medical Systems
Merit Medical Systems Inc (NASDAQ:MMSI) is a medical device company that designs, develops, and markets single-use medical products for various medical procedures. The company operates in two main segments: Cardiovascular and Endoscopy, offering a wide range of products, including micropuncture kits, angiographic needles, sheaths, guide wires, and safety products, among others.
From a business perspective, Merit Medical Systems has a diverse product portfolio that caters to different medical specialties, including cardiology, oncology, and gastroenterology. The companys products are sold through various channels, including direct sales force, distributors, and original equipment manufacturer partners. With a global presence, Merit Medical Systems has established itself as a significant player in the medical device industry.
To evaluate the companys performance, some key performance indicators (KPIs) can be considered. For instance, revenue growth, gross margin, and operating margin are essential metrics to assess the companys financial health. Additionally, metrics such as return on equity (RoE) and return on assets (RoA) can provide insights into the companys ability to generate profits from its equity and assets. With a RoE of 9.03%, Merit Medical Systems has demonstrated a reasonable ability to generate returns for its shareholders.
From a valuation perspective, the companys price-to-earnings (P/E) ratio and forward P/E ratio can be used to assess its relative valuation. With a P/E ratio of 41.70 and a forward P/E ratio of 26.25, Merit Medical Systems may be considered relatively expensive compared to its earnings. However, this needs to be evaluated in the context of the companys growth prospects and industry peers.
Overall, Merit Medical Systems appears to be a well-established player in the medical device industry, with a diverse product portfolio and global presence. To make an informed investment decision, it is essential to continue monitoring the companys financial performance, industry trends, and competitive landscape.
MMSI Stock Overview
| Market Cap in USD | 5,258m |
| Sub-Industry | Health Care Supplies |
| IPO / Inception | 1990-08-09 |
MMSI Stock Ratings
| Growth Rating | 21.6% |
| Fundamental | 70.1% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -27.4% |
| Analyst Rating | 4.30 of 5 |
MMSI Dividends
Currently no dividends paidMMSI Growth Ratios
| Growth Correlation 3m | -36% |
| Growth Correlation 12m | -64.7% |
| Growth Correlation 5y | 87.2% |
| CAGR 5y | 13.98% |
| CAGR/Max DD 3y | 0.53 |
| CAGR/Mean DD 3y | 2.28 |
| Sharpe Ratio 12m | 0.32 |
| Alpha | -26.81 |
| Beta | 0.644 |
| Volatility | 29.20% |
| Current Volume | 700.2k |
| Average Volume 20d | 503.6k |
| Stop Loss | 82.9 (-3.1%) |
| Signal | -1.39 |
Piotroski VR‑10 (Strict, 0-10) 7.5
| Net Income (119.1m TTM) > 0 and > 6% of Revenue (6% = 86.0m TTM) |
| FCFTA 0.09 (>2.0%) and ΔFCFTA 1.24pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 48.68% (prev 75.13%; Δ -26.45pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.09 (>3.0%) and CFO 240.0m > Net Income 119.1m (YES >=105%, WARN >=100%) |
| Net Debt (476.7m) to EBITDA (307.3m) ratio: 1.55 <= 3.0 (WARN <= 3.5) |
| Current Ratio 4.09 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (60.6m) change vs 12m ago 3.19% (target <= -2.0% for YES) |
| Gross Margin 47.95% (prev 45.35%; Δ 2.59pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 57.80% (prev 54.79%; Δ 3.01pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 6.25 (EBITDA TTM 307.3m / Interest Expense TTM 28.8m) >= 6 (WARN >= 3) |
Altman Z'' 4.64
| (A) 0.27 = (Total Current Assets 923.1m - Total Current Liabilities 225.6m) / Total Assets 2.59b |
| (B) 0.29 = Retained Earnings (Balance) 758.3m / Total Assets 2.59b |
| (C) 0.07 = EBIT TTM 180.2m / Avg Total Assets 2.48b |
| (D) 1.36 = Book Value of Equity 1.49b / Total Liabilities 1.10b |
| Total Rating: 4.64 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 70.06
| 1. Piotroski 7.50pt = 2.50 |
| 2. FCF Yield 3.99% = 2.00 |
| 3. FCF Margin 15.76% = 3.94 |
| 4. Debt/Equity 0.50 = 2.38 |
| 5. Debt/Ebitda 2.41 = -0.80 |
| 6. ROIC - WACC -0.69% = -0.86 |
| 7. RoE 8.48% = 0.71 |
| 8. Rev. Trend 97.68% = 4.88 |
| 9. Rev. CAGR 10.98% = 1.37 |
| 10. EPS Trend 57.68% = 1.44 |
| 11. EPS CAGR 29.29% = 2.50 |
What is the price of MMSI shares?
Over the past week, the price has changed by -7.36%, over one month by +0.36%, over three months by -8.79% and over the past year by -14.16%.
Is Merit Medical Systems a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of MMSI is around 83.55 USD . This means that MMSI is currently overvalued and has a potential downside of -2.31%.
Is MMSI a buy, sell or hold?
- Strong Buy: 4
- Buy: 5
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the MMSI price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 103.6 | 21.1% |
| Analysts Target Price | 103.6 | 21.1% |
| ValueRay Target Price | 92.3 | 7.9% |
Last update: 2025-09-12 04:41
MMSI Fundamental Data Overview
CCE Cash And Equivalents = 343.9m USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 45.0711
P/E Forward = 22.5734
P/S = 3.6697
P/B = 3.5335
P/EG = 1.9646
Beta = 0.641
Revenue TTM = 1.43b USD
EBIT TTM = 180.2m USD
EBITDA TTM = 307.3m USD
Long Term Debt = 731.8m USD (from longTermDebt, last quarter)
Short Term Debt = 10.3m USD (from shortTermDebt, last quarter)
Debt = 742.1m USD (Calculated: Short Term 10.3m + Long Term 731.8m)
Net Debt = 476.7m USD (from netDebt column, last quarter)
Enterprise Value = 5.66b USD (5.26b + Debt 742.1m - CCE 343.9m)
Interest Coverage Ratio = 6.25 (Ebit TTM 180.2m / Interest Expense TTM 28.8m)
FCF Yield = 3.99% (FCF TTM 225.8m / Enterprise Value 5.66b)
FCF Margin = 15.76% (FCF TTM 225.8m / Revenue TTM 1.43b)
Net Margin = 8.31% (Net Income TTM 119.1m / Revenue TTM 1.43b)
Gross Margin = 47.95% ((Revenue TTM 1.43b - Cost of Revenue TTM 745.8m) / Revenue TTM)
Tobins Q-Ratio = 3.80 (Enterprise Value 5.66b / Book Value Of Equity 1.49b)
Interest Expense / Debt = 0.91% (Interest Expense 6.78m / Debt 742.1m)
Taxrate = 19.76% (29.6m / 150.0m)
NOPAT = 144.6m (EBIT 180.2m * (1 - 19.76%))
Current Ratio = 4.09 (Total Current Assets 923.1m / Total Current Liabilities 225.6m)
Debt / Equity = 0.50 (Debt 742.1m / last Quarter total Stockholder Equity 1.49b)
Debt / EBITDA = 2.41 (Net Debt 476.7m / EBITDA 307.3m)
Debt / FCF = 3.29 (Debt 742.1m / FCF TTM 225.8m)
Total Stockholder Equity = 1.40b (last 4 quarters mean)
RoA = 4.61% (Net Income 119.1m, Total Assets 2.59b )
RoE = 8.48% (Net Income TTM 119.1m / Total Stockholder Equity 1.40b)
RoCE = 8.44% (Ebit 180.2m / (Equity 1.40b + L.T.Debt 731.8m))
RoIC = 6.76% (NOPAT 144.6m / Invested Capital 2.14b)
WACC = 7.44% (E(5.26b)/V(6.00b) * Re(8.39%)) + (D(742.1m)/V(6.00b) * Rd(0.91%) * (1-Tc(0.20)))
Shares Correlation 3-Years: 87.88 | Cagr: 0.47%
Discount Rate = 8.39% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 80.33% ; FCFE base≈206.6m ; Y1≈254.9m ; Y5≈434.8m
Fair Price DCF = 116.8 (DCF Value 6.91b / Shares Outstanding 59.2m; 5y FCF grow 25.0% → 3.0% )
Revenue Correlation: 97.68 | Revenue CAGR: 10.98%
Rev Growth-of-Growth: 1.23
EPS Correlation: 57.68 | EPS CAGR: 29.29%
EPS Growth-of-Growth: -22.59
Additional Sources for MMSI Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle